ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
ADMA Biologics ADMA and Takeda TAK are leading players in the plasma derived immunoglobulin sector.
ADMA markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.
On the other hand, Takeda has a well-diversified business with a focus on gastroenterology (GI), rare diseases, plasma-derived therapies (PDT), oncology and neuroscience.
Given the companies' commanding position in the plasma-derived therapies market, choosing one stock over another can be challenging. Let us delve into their fundamentals, potential growth prospects, challenges and valuation levels to make a prudent choice.
ADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.
The company's top line currently comprises sales of three FDA-approved products — Bivigam (an Intravenous Immune Globulin ['IVIG'] product to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency disease or PIDD) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus).
Asceniv, its lead product, is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies. These antibodies are proteins used by the body's immune system to neutralize microbes, such as bacteria and viruses, and prevent infections and diseases.
Asceniv is indicated for the treatment of PIDD or inborn errors of immunity in adults and adolescents. It is manufactured using ADMA's unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma with respiratory syncytial virus plasma obtained from donors tested using the company's proprietary microneutralization assay.
Demand was record high in the first quarter. Consequently, ADMA expects Asceniv's total revenue share to expand throughout 2025 and beyond.
ADMA plans to file a supplemental biologics license application in mid-2025 for the expansion of Asceniv's label to include the pediatric setting for patients who are two years and older.
ADMA expects to generate initial, proof-of-concept animal data before 2025-end for its lead pipeline program, SG-001, a hyperimmune globulin targeting S. pneumonia. It believes that SG-001 has the potential to generate $300-500 million or more in high-margin annual revenues, with IP protection through at least 2037.
Takeda is focused on developing life-saving plasma-derived therapies, which are essential for patients with a variety of rare and complex chronic diseases. Takeda has created a dedicated PDT business unit that manages the business end-to-end, from plasma donation to manufacturing, R&D and commercialization.
The PDT business posted 9% growth in 2024. Takeda's broad immunoglobulin portfolio includes Hyqvia, Cuvitru, Gammagard Liquid and Gammagard S/D. Among these, Hyqvia is a product consisting of human normal IG and recombinant human hyaluronidase (licensed from Halozyme).
Hyqvia is the only subcutaneous IG treatment for primary immunodeficiencies (PID) patients with a dosing regimen that requires only one infusion up to once per month and one injection site per infusion to deliver a full therapeutic dose of IG. It is approved in the United States for adults with PID, and in Europe for patients with PID syndromes and myeloma or CLL with severe secondary hypogammaglobulinemia and recurrent infections. Hyqvia was also approved for maintenance treatment in adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) in the United States and CIDP patients of all ages in Europe.
Gammagard Liquid/Kiovig is a liquid formulation of the antibody replacement therapy immunoglobulin (IG), for the treatment of adult and pediatric patients two years of age or older with PID and adult patients with multifocal motor neuropathy (MMN) (administered intravenously). It is also approved for adult patients with CIDP. Kiovig is the brand name used for Gammagard Liquid in many countries outside the United States.
Cuvitru is indicated as replacement therapy for primary humoral immunodeficiency in adults and pediatric patients two years of age and older.
The PDT business is one of the focal areas for Takeda's R&D efforts. The company is developing next-generation immunoglobulin products with 20% facilitated SCIG (TAK-881) and liquid low IgA IG (TAK-880). It is also pursuing other early-stage opportunities (e.g., hypersialylated Immunoglobulin [hsIgG]) that would diversify its portfolio further.
The company has also joined forces with Halozyme, Kamada, and Johnson & Johnson to advance its pipeline further.
The Zacks Consensus Estimate for ADMA's 2025 sales implies a year-over-year increase of 18.61%, and that for earnings per share (EPS) suggests an improvement of 36.73%. However, EPS estimates for 2025 have moved south in the past 60 days. Nonetheless, the metric for 2026 has moved north during the same time frame.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for TAK's 2025 sales implies a year-over-year decrease of 2.80%, while that for EPS suggests an improvement of 6.21%. However, EPS estimates for 2025 and 2026 have moved south in the past 60 days.
Image Source: Zacks Investment Research
From the perspective of price performance, TAK has fetched better returns than ADMA so far this year. Shares of ADMA have gained 4.1%, while those of TAK have risen 13.91%.
Image Source: Zacks Investment Research
From a valuation standpoint, ADMA is more expensive than TAK. ADMA's shares currently trade at 21.79X forward earnings, higher than 9.03X for TAK.
Image Source: Zacks Investment Research
Large biotech companies are generally considered safe havens for investors interested in this sector.
Takeda is a drug giant with an extremely broad and diverse portfolio. It is one of the three largest producers of plasma derivatives in terms of total sales. TAK's diversified plasma drug portfolio, global infrastructure, and encouraging R&D efforts should help it drive growth in its PDT business.
TAK currently carries a Zacks Rank #4 (Sell).
On the other hand, ADMA's top line is witnessing steady growth on the back of robust Asceniv demand. An acceleration in new patient starts, a potential label expansion and further penetration in existing markets should significantly expand Asceniv's sales.
ADMA currently carries a Zacks #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
While large-cap TAK provides stability and has provided better returns than ADMA so far this year, we believe ADMA's revenue potential to be further unlocked with the market expansion of Asceniv, positioning it for solid growth. Hence, ADMA is a better pick at present.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADMA Biologics Inc (ADMA) : Free Stock Analysis Report
Takeda Pharmaceutical Co. (TAK) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
3 hours ago
- Chicago Tribune
FDA requires updated warning about rare heart risk with COVID shots
WASHINGTON — The Food and Drug Administration said Wednesday it has expanded existing warnings on the two leading COVID-19 vaccines about a rare heart side effect mainly seen in young men. Myocarditis, a type of heart inflammation that is usually mild, emerged as a complication after the first shots became widely available in 2021. Prescribing information from both Pfizer and Moderna already advises doctors about the issue. In April, the FDA sent letters to both drugmakers asking them to update and expand the warnings to add more detail about the problem and to cover a larger group of patients. While the FDA can mandate label changes, the process is often more of a negotiation with companies. Specifically, the new warning lists the risk of myocarditis as 8 cases per 1 million people who got the 2023-2024 COVID shots between the ages of 6 months and 64 years old. The label also notes that the problem has been most common among males ages 12 to 24. The previous label said the problem mostly occurs in 12- to 17-year-olds. The FDA's labeling change appears to conflict with some prior findings of scientists elsewhere in the U.S. government. The Centers for Disease Control and Prevention previously concluded there was no increased risk of myocarditis detected in government vaccine injury databases for COVID-19 shots dating back to 2022. Officials also noted that cases tend to resolve quickly and are less severe than those associated with COVID-19 infection itself, which can also cause myocarditis. The FDA announcement came as new vaccine advisers appointed by Health Secretary Robert F. Kennedy Jr. met to debate the continuing use of COVID-19 vaccines for key groups, including pregnant women. It's the first meeting of the CDC advisory panel since Kennedy abruptly dismissed all 17 members of the group, naming a new panel that includes several members with a history of anti-vaccine statements. The FDA's label update is the latest step by officials working under Kennedy to restrict or undercut use of vaccines. FDA Commissioner Marty Makary and a top deputy recently restricted annual COVID-19 shots to seniors and other Americans at higher risk from the virus. They've also suggested seasonal tweaks to match the latest circulating virus strains are new products that require extra testing. Outside experts said the new warning is the wrong approach. 'They are right to suggest that we need to consider myocarditis risks associated with the vaccine, but what they propose is exactly the wrong solution,' said Dr. Robert Morris, a public health specialist at the University of Washington. 'We should be investigating who is prone to myocarditis to see if we can predict and mitigate that risk.' Makary and several other FDA officials gained prominence during the pandemic by suggesting the federal government exaggerated the benefits of COVID-19 boosters and downplayed serious side effects, including myocarditis. Before joining the government, Makary and two of his current FDA deputies wrote a 2022 paper that said mandating booster shots in young people would cause more vaccine-related injuries than prevented hospitalizations from COVID-19 infections. The conclusion contradicted that of many leading vaccine and public health experts at the time, including at the CDC.
Yahoo
3 hours ago
- Yahoo
DHODH Inhibitors Market Forecast to Reach New Heights by 2034 Owing to the Expanding Applications in Oncology and Autoimmune Diseases
The DHODH inhibitor market is poised for steady growth, fueled by the rising burden of autoimmune and inflammatory diseases, along with increasing interest in targeting metabolic pathways in oncology and Immunology. While only two agents, leflunomide and teriflunomide, are currently approved, a growing clinical pipeline featuring candidates from companies like Immunic Therapeutics, Jabez Bioscience, and others suggests expanded therapeutic potential beyond traditional autoimmune indications. LAS VEGAS, June 25, 2025 /PRNewswire/ -- DelveInsight's DHODH Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as multiple sclerosis, ulcerative colitis, rheumatoid arthritis, NHL, and even viral infections. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging DHODH inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM. Key Takeaways from the DHODH Inhibitors Market Report As per DelveInsight's analysis, the total market size of DHODH inhibitors in the 7MM is expected to surge significantly by 2034. The report provides the total potential number of patients in the indications, such as multiple sclerosis, ulcerative colitis, rheumatoid arthritis, NHL, and even viral infections. Leading DHODH inhibitors companies, such as Immunic Therapeutics, Aslan Pharmaceuticals, Jabez Bioscience, and others, are developing novel DHODH inhibitors that can be available in the DHODH inhibitors market in the coming years. Some of the key DHODH inhibitors in the pipeline include Vidofludimus Calcium (IMU-838), Farudodstat, JBZ-001, and others. Discover which indication is expected to grab the major DHODH inhibitors market share @ DHODH Inhibitors Market Report DHODH Inhibitors Market Dynamics The dihydroorotate dehydrogenase (DHODH) inhibitors market is witnessing growing interest due to the enzyme's critical role in the de novo pyrimidine biosynthesis pathway, which is essential for DNA and RNA synthesis. DHODH inhibitors block this mitochondrial enzyme, thereby curbing nucleotide synthesis and impeding the proliferation of rapidly dividing cells. This mechanism has significant therapeutic potential, particularly in oncology, autoimmune diseases, and viral infections. As a result, pharmaceutical companies are increasingly investing in the research and development of novel DHODH inhibitors, both as monotherapies and in combination with other agents. One of the major drivers of this market is the increased focus on targeted therapies in cancer treatment. Moreover, recent research indicates potential synergy when DHODH inhibitors are combined with other agents like BCL-2 or FLT3 inhibitors, opening avenues for combination therapies that may overcome resistance and improve patient outcomes. Additionally, the repurposing of DHODH inhibitors, such as leflunomide, initially developed for autoimmune diseases, has further catalyzed interest in this class of drugs. On the other hand, market growth is constrained by several challenges. The specificity and safety profiles of DHODH inhibitors remain areas of concern, as off-target effects or immunosuppressive consequences could limit their utility. Furthermore, competition from other targeted therapies and small molecules with established clinical efficacy can make market penetration difficult for newer DHODH inhibitors. Regulatory hurdles and the need for biomarker-driven patient stratification also add complexity to development and commercialization efforts. Looking forward, the DHODH inhibitor market is poised for steady growth, propelled by advancements in molecular biology, increasing unmet medical needs in oncology and autoimmune conditions, and the evolving landscape of precision medicine. Strategic partnerships, licensing deals, and successful late-stage trials will be critical in shaping the commercial success of emerging candidates. As the field matures, the development of next-generation DHODH inhibitors with enhanced selectivity and fewer side effects will be essential for capturing greater market share and achieving long-term clinical and commercial impact. DHODH Inhibitors Treatment Market In recent years, DHODH inhibitors have gained attention as a promising treatment strategy for chronic inflammatory and autoimmune disorders, including multiple sclerosis, ulcerative colitis, rheumatoid arthritis, and non-Hodgkin lymphoma. By targeting de novo pyrimidine synthesis, these agents effectively modulate immune responses, offering potential as disease-modifying therapies. Currently, only two DHODH inhibitors have been approved: leflunomide and its active metabolite, teriflunomide. Leflunomide, available generically, is mainly prescribed for rheumatoid arthritis, while teriflunomide, marketed as AUBAGIO, is approved for multiple sclerosis and became available in generic form in 2023. No other agents in this class have received regulatory approval so far. However, a number of novel candidates are undergoing clinical trials for autoimmune conditions, cancers, and viral infections, reflecting a growing interest in the target. Ongoing clinical results continue to demonstrate their potential, reinforcing the role of DHODH inhibitors as promising additions to the immunology drug pipeline. Learn more about the DHODH inhibitors @ DHODH Inhibitors Analysis Key Emerging DHODH Inhibitors and Companies Some of the emerging DHODH inhibitors in the pipeline include Vidofludimus Calcium (IMU-838) (Immunic Therapeutics), Farudodstat (Aslan Pharmaceuticals), JBZ-001 (Jabez Bioscience), and others. Vidofludimus calcium is an investigational oral small-molecule drug being developed as a next-generation therapy for multiple sclerosis and various chronic inflammatory and autoimmune conditions. It functions as a selective immune modulator by activating the neuroprotective transcription factor Nurr1 (nuclear receptor-related 1), which plays a role in promoting nerve cell protection. Additionally, the compound is a potent and selective inhibitor of the enzyme DHODH, essential for the metabolic processes of overactive immune and virus-infected cells. This dual mechanism contributes to its anti-inflammatory and antiviral properties. Also known as IMU-838, the drug is currently being evaluated in Phase III and Phase II clinical trials for relapsing and progressive forms of multiple sclerosis, respectively. It has shown therapeutic benefit in earlier Phase II trials across relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. JBZ-001 is another orally available small-molecule DHODH inhibitor, developed to interfere with the de novo pyrimidine nucleotide biosynthesis pathway, an essential process for the proliferation of cancer cells. By inhibiting DHODH, the pathway's rate-limiting enzyme, JBZ-001 has demonstrated cytotoxic potential against tumor cells, positioning it as a promising candidate in oncology. The compound, developed under Jabez Biosciences' translational research efforts, received FDA clearance for a commercial IND application in 2024 and is currently in Phase I trials for advanced solid tumors and hematologic cancers. The anticipated launch of these emerging therapies are poised to transform the DHODH inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the DHODH inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about DHODH inhibitors clinical trials, visit @ DHODH Inhibitors Treatment DHODH Inhibitors Overview DHODH inhibitors are a group of drugs that target and block the activity of the DHODH enzyme, which plays a vital role in the mitochondrial pathway responsible for de novo pyrimidine synthesis, crucial building blocks for DNA and RNA. By disrupting this process, these drugs reduce the supply of pyrimidines, thereby hindering DNA production and triggering cell cycle arrest, especially in fast-dividing cells. These agents are primarily used in conditions marked by excessive immune response or abnormal cell growth. In autoimmune diseases such as rheumatoid arthritis and multiple sclerosis, they help restrain the proliferation of overactive immune cells. In cancer, DHODH inhibitors are under investigation for their ability to impede tumor growth, as cancer cells depend heavily on continuous nucleotide production. This targeted mode of action makes DHODH inhibitors a promising therapeutic option for managing various diseases driven by uncontrolled cell proliferation. DHODH Inhibitors Epidemiology Segmentation The DHODH inhibitors market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases in Selected Indications for DHODH Inhibitors Total Eligible Patient Pool in Selected Indications for DHODH Inhibitors Total Treated Cases in Selected Indications for DHODH Inhibitors DHODH Inhibitors Report Metrics Details Study Period 2020–2034 DHODH Inhibitors Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Indications Covered in the Report Multiple sclerosis, ulcerative colitis, rheumatoid arthritis, NHL, and even viral infections Key DHODH Inhibitors Companies Immunic Therapeutics, Aslan Pharmaceuticals, Jabez Bioscience, and others Key DHODH Inhibitors Vidofludimus Calcium (IMU-838), Farudodstat, JBZ-001, leflunomide and teriflunomide (AUBAGIO, generic since 2023), and others Scope of the DHODH Inhibitors Market Report DHODH Inhibitors Therapeutic Assessment: DHODH Inhibitors current marketed and emerging therapies DHODH Inhibitors Market Dynamics: Conjoint Analysis of Emerging DHODH Inhibitors Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, DHODH Inhibitors Market Access and Reimbursement Discover more about DHODH inhibitors in development @ DHODH Inhibitors Clinical Trials Table of Contents 1. Key Insights 2. Report Introduction 3. Executive Summary 4. Key Events 5. Epidemiology and Market Forecast Methodology 6. DHODH Inhibitors Market Overview at a Glance in the 7MM 6.1. Market Share (%) Distribution by Therapies in 2025 6.2. Market Share (%) Distribution by Therapies in 2034 6.3. Market Share (%) Distribution by Indications in 2025 6.4. Market Share (%) Distribution by Indications in 2034 7. DHODH Inhibitors: Background and Overview 7.1. Introduction 7.2. Potential of DHODH Inhibitors in Different Indications 7.3. Clinical Applications of DHODH Inhibitors 8. Target Patient Pool of DHODH Inhibitors 8.1. Assumptions and Rationale 8.2. Key Findings 8.3. Total Cases of Selected Indication for DHODH Inhibitors in the 7MM 8.4. Total Eligible Patient Pool of Selected Indication for DHODH Inhibitors in the 7MM 8.5. Total Treatable Cases in Selected Indications for DHODH Inhibitors in the 7MM 9. Emerging Therapies 9.1. Key Competitors 9.2. Vidofludimus Calcium (IMU-838): Immunic Therapeutics 9.2.1. Product Description 9.2.2. Other developmental activities 9.2.3. Clinical development 9.2.4. Safety and efficacy 9.3. JBZ-001: Jabez Bioscience 9.3.1. Product Description 9.3.2. Other developmental activities 9.3.3. Clinical development 9.3.4. Safety and efficacy List to be continued in the report 10. DHODH Inhibitors: Seven Major Market Analysis 10.1. Key Findings 10.2. Market Outlook 10.3. Conjoint Analysis 10.4. Key Market Forecast Assumptions 10.4.1. Cost Assumptions and Rebates 10.4.2. Pricing Trends 10.4.3. Analogue Assessment 10.4.4. Launch Year and Therapy Uptakes 10.5. Total Market Sizes of DHODH Inhibitors by Indications in the 7MM 10.6. The United States Market Size 10.6.1. Total Market Size of DHODH Inhibitors in the United States 10.6.2. Market Size of DHODH Inhibitors by Indication in the United States 10.6.3. Market Size of DHODH Inhibitors by Therapies in the United States 10.7. EU4 and the UK 10.7.1. Total Market Size of DHODH Inhibitors in EU4 and the UK 10.7.2. Market Size of DHODH Inhibitors by Indications in EU4 and the UK 10.7.3. Market Size of DHODH Inhibitors by Therapies in EU4 and the UK 10.8. Japan 10.8.1. Total Market Size of DHODH Inhibitors in Japan 10.8.2. Market Size of DHODH Inhibitors by Indications in Japan 10.8.3. Market Size of DHODH Inhibitors by Therapies in Japan 11. SWOT Analysis 12. KOL Views 13. Unmet Needs 14. Market Access and Reimbursement 15. Appendix 15.1. Bibliography 15.2. Report Methodology 16. DelveInsight Capabilities 17. Disclaimer 18. About DelveInsight Related Reports Ulcerative Colitis Market Ulcerative Colitis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ulcerative colitis companies, including Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, NImmune, Merck, Mesoblast, among others. Non-Hodgkin's Lymphoma Market Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NHL companies, including AbbVie, Genmab, Novartis, Angiocrine Bioscience, Autolus, Zentera Therapeutics, Jiangsu Hengrui Medicine, among others. Multiple Sclerosis Market Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple sclerosis companies, including Novartis, Sanofi, AB Science, Roche, Clene Nanomedicine, InnoCare Pharma, among others. Rheumatoid Arthritis Market Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key rheumatoid arthritis companies, including R-Pharm, Taisho Pharmaceuticals, GlaxoSmithKline, Aclaris Therapeutics, Bristol Myers Squibb, Eli Lilly, Taiho Pharmaceutical, Cyxone, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, Applied Molecular Transport, Horizon Therapeutics, Genosco (Oscotec), Hope Biosciences, Abivax, Mesoblast, Akros Pharma, Japan Tobacco, Pfizer, Philogen, AbbVie, Pfizer, SynAct Pharma, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
3 hours ago
- Miami Herald
Bacteria that can cause vomiting, diarrhea gets kids' cough syrup recalled
Parents, guardians and all who care for kids should check their medicine cabinets after a children's cough syrup was recalled for a foodborne bacteria that can cause myriad problems. And, in extreme cases, cause death. Medtech Products' recall notice, posted to the FDA website, said it recalled five lots of Little Remedies Honey Cough Syrup for the 'presence of Bacillus cereus and loss of shelf-stability.' That bacteria can bring on two kinds of foodborne illnesses. 'One type is characterized by nausea, vomiting, and stomach cramps that can start one to six hours after eating or drinking contaminated food,' Medtech's notice said. 'The second type can cause stomach cramps and diarrhea that can start eight to 16 hours after eating or drinking contaminated food. 'Although healthy individuals may suffer only short-term illness, exposure to high levels of foodborne B. cereus can cause death.' Recalled lot Nos. are 0039, expiration date 11/2025; 0545, expiration date 1/2026; 0640, expiration date 2/2026; 0450, expiration date 5/2026; and 1198, expiration date 12/2026. For refunds, Medtech is asking customers to go to the Prestige Brands website, email medicalaffairs@ or call 800-754-8853, Monday through Friday, 8:30 a.m. to 5:30 p.m., Eastern time. Any medical problems should be taken to a medical professional first. Then notify the FDA's MedWatch program by filling out a report online. After that, tell Medtech.
